Nuwellis, Inc. filings document a Nasdaq-listed medical technology issuer focused on cardiorenal care and ultrafiltration therapy. Form 8-K reports cover operating results, material events, clinical or regulatory disclosures, board appointments and resignations, and resolved litigation matters, while proxy materials describe director elections, auditor ratification, board committee governance, executive compensation, and stockholder voting matters.
Nuwellis, Inc. filed a Form 8-K reporting that it entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. dated September 3, 2025. The filing lists an opinion and consent from Honigman LLP as exhibits. The document indicates the company has established a mechanism to offer its common stock (NUWE) into the market under the agreement, and the related legal opinion and consent are included as exhibits.
Nuwellis, Inc. has filed a prospectus supplement to offer up to $4,650,000 of common stock in an at-the-market program with Ladenburg Thalmann & Co. Inc., which may act as agent or principal and receive commissions of up to 3.0% of gross sales. The filing states there is no escrow arrangement and the agent will be deemed an underwriter for Securities Act purposes with customary indemnification rights.
The company discloses corporate and capital information: common stock trades on Nasdaq under NUWE, last reported sale price was $5.18 on August 28, 2025, and public float computed on July 16, 2025 was $13,977,751 based on 876,348 non-affiliate shares at $15.95. The prospectus reports 902,665 shares outstanding as of August 8, 2025 and lists various dilutive instruments including warrants and convertible preferred shares. Auditors Baker Tilly included an explanatory paragraph regarding the company's ability to continue as a going concern. The company also disclosed a non-binding LOI to acquire Rendiatech, Ltd., with a potential close in the fourth quarter of 2025 pending board approval and closing conditions.
Nuwellis, Inc. announced it received U.S. Food and Drug Administration 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). The filing is brief and states the clearance date as August 21, 2025. This indicates the company added a cleared product variant to its U.S. regulatory portfolio, which may support future clinical use and commercial availability of the dELC family.
The 8-K does not disclose pricing, launch timing, shipment volumes, or expected revenue impact. Investors should note this is a regulatory clearance for a device size variant rather than a new device model and the company provided no operational or financial details in the filing.
Nuwellis announced a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli medical device company focused on real-time urine flow and acute kidney injury monitoring technologies. The proposed deal is described as supporting Nuwellis’s aim to expand its platform beyond ultrafiltration by potentially adding continuous renal health monitoring that can give clinicians earlier insight into fluid status and kidney function. The parties are conducting due diligence and, if they agree to proceed, the company expects the transaction to close in the fourth quarter of 2025, subject to final board approval and closing conditions. The filing also includes standard forward-looking statement disclosures noting risks such as execution, financing, integration, and other uncertainties.
Nuwellis, Inc. reported that it has released its financial results for the three and six months ended June 30, 2025. The company furnished this update through a press release dated August 14, 2025, which is attached as Exhibit 99.1. The information was provided under a current report and is treated as furnished rather than filed under securities law, which affects how it is subject to certain legal liabilities.
Nuwellis, Inc. (NUWE) filed an 8-K to report that it has regained compliance with Nasdaq’s $1.00 minimum bid-price rule. On 18 Jun 2025 the company received a deficiency notice because its shares closed below $1.00 for 30 straight trading days and, due to recent reverse splits, NUWE was ineligible for the standard 180-day cure period. Nasdaq therefore set a delisting hearing for 12 Aug 2025.
On 22 Jul 2025 Nasdaq’s Office of General Counsel informed the company that the bid-price deficiency has been cured; consequently, the hearing was cancelled and NUWE’s common stock will continue trading on the Nasdaq Capital Market. The filing eliminates an immediate delisting threat but highlights prior share-price weakness that triggered the notice.
Nuwellis, Inc. (NASDAQ: NUWE) has issued a Definitive Proxy Statement for a virtual special meeting on 4 Aug 2025. Shareholders of record on 9 Jun 2025 (130,154 shares outstanding, post-1-for-42 split) are asked to vote on four key items:
- Proposal 1 – Warrant Exercise Approval: Permit the issuance of up to 1,599,214 common shares upon exercise of Series A, Series B and underwriter warrants sold in the $5 million June 2025 financing. Warrants carry a $12.60 exercise price (cash) and a five-year term once shareholder approval is obtained; Series A warrants include a one-time price reset tied to any future reverse split, and Series B warrants allow cashless exercise.
- Proposal 2 – Authorized Share Increase: Double authorized common stock to 200 million shares to enhance capital-raising flexibility. No immediate issuance is planned, but the new shares would have rights identical to existing common stock.
- Proposal 3 – Reverse Stock Split Authority: Authorize the Board to implement, within 12 months, a split in the range of 1-for-5 to 1-for-70. The measure is intended to help the company maintain compliance with Nasdaq listing requirements should future bid-price weakness re-emerge. Fractional shares will be rounded down for cash.
- Proposal 4 – Adjournment Authority: Allow one or more adjournments if insufficient votes are received for Proposals 1-3.
Strategic Rationale
- Warrant exercise could provide up to $3.25 million of additional cash (assuming full cash exercise at current prices), supporting working-capital needs and clinical programs.
- Reverse split flexibility is positioned as a tool to protect Nasdaq listing status after previous bid-price deficiencies and repeated reverse splits (1-for-35 in Jun 2024 and 1-for-42 in Jul 2025).
- Increasing the authorized share pool preserves headroom for future financing, equity incentives, strategic transactions and potential anti-takeover defense.
Potential Investor Impact
- The full warrant exercise would expand the current share count by more than ten-fold, causing substantial dilution.
- Stockholders could face further dilution from any future issuances under the expanded authorization.
- Reverse splits do not change proportional ownership but often reduce liquidity and may signal financial distress.
- Failure to pass Proposal 1 obliges the company to call new meetings every 40 days, increasing cost and management distraction.
The Board unanimously recommends “FOR” on all four proposals.